These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 7254439)
1. The macrophage electrophoretic mobility assay in patients with renal cell carcinoma. Malkovský M; Bubeník J; Jakoubková J; Suhajová E; Indrová M; Jandlová T; Símová J Neoplasma; 1981; 28(2):245-51. PubMed ID: 7254439 [TBL] [Abstract][Full Text] [Related]
2. Lymphocyte sensitization detected by the macrophage electrophoretic mobility assay in patients with renal cell carcinoma: Theophylline increases the sensitivity of the assay. Malkovský M; Bubeník J; Malkovská V; Indrová M; Suhajová E; Jakoubková J; Jíra M Arch Geschwulstforsch; 1981; 51(4):364-70. PubMed ID: 7032451 [TBL] [Abstract][Full Text] [Related]
3. Tumor membrane lymphocyte stimulation assay in patients with renal cell carcinoma. Hemstreet GP; Dawson JR; Seigler HF Cancer Res; 1978 May; 38(5):1447-56. PubMed ID: 646859 [TBL] [Abstract][Full Text] [Related]
4. [Reaction of inhibition of macrophage electrophoretic mobility in differential diagnosis of carcinomas]. Miuller M; Irmsher Iu; Fisher R; Grosmann G Vopr Onkol; 1976; 22(12):43-50. PubMed ID: 1020256 [TBL] [Abstract][Full Text] [Related]
5. Studies with the macrophage migration inhibition (MMI) test in patients with malignant disease. Light PA; Preece AW; Waldron HA Clin Exp Immunol; 1975 Nov; 22(2):279-84. PubMed ID: 55328 [TBL] [Abstract][Full Text] [Related]
6. A comparison of the macrophage electrophoretic mobility test and the leukocyte migration inhibition test in the detection of histocompatibility antigens on tumor cells. Bubeník J; Cochran AJ; Todd G; Malkovský M; Jandlová T; Suhajová E; Boubelík M Neoplasma; 1981; 28(2):185-93. PubMed ID: 7019742 [TBL] [Abstract][Full Text] [Related]
7. The macrophage electrophoretic migration (MEM) test for lymphocyte sensitization. A study of the kinetics. Carnegie PR; Caspary EA; Dickinson JP; Field EJ Clin Exp Immunol; 1973 May; 14(1):37-45. PubMed ID: 4716103 [TBL] [Abstract][Full Text] [Related]
8. [Determination of the MSF (macrophage slowing factor) release by phytohemagglutinin using the macrophage electrophoretic mobility test (MEM test). I. Dependency of release on incubation time, phytohemagglutinin and cell concentration]. Metzner G; Jäger L Acta Biol Med Ger; 1980; 39(2-3):223-7. PubMed ID: 6999821 [TBL] [Abstract][Full Text] [Related]
9. Sensitization of normal mouse lymphocytes immunized in vitro as detected by macrophage electrophoretic mobility (MEM) test. Nĕmecková S; Bubeník J; Indrová M Folia Biol (Praha); 1982; 28(4):280-2. PubMed ID: 7141039 [TBL] [Abstract][Full Text] [Related]
10. Isolation of a soluble tumor-associated antigen from human renal cell carcinoma by gradient acrylamide gel electrophoresis. Wright GL; Schellhammer PF; Faulconer RL Cancer Res; 1977 Nov; 37(11):4228-32. PubMed ID: 911404 [No Abstract] [Full Text] [Related]
11. The macrophage electrophoretic mobility (MEM) test for malignant disease. Further clinical investigations and studies on macrophage slowing factors. Preece AW; Light PA Clin Exp Immunol; 1974 Dec; 18(4):543-52. PubMed ID: 4143199 [TBL] [Abstract][Full Text] [Related]
12. The use of the macrophage electrophoretic mobility test for the diagnosis of eye diseases. Jenssen R; Jenssen HL; Köhler H; Friemel H Mod Probl Ophthalmol; 1976; 16():259-64. PubMed ID: 943037 [TBL] [Abstract][Full Text] [Related]
14. Reactivity of human lymphocytes to teratoma preparations as revealed by the macrophage electrophoretic mobility (MEM) technique. Irmscher J; Grossmann H; Kotzsch M; Wagner H; Müller M Arch Geschwulstforsch; 1982; 52(5):349-53. PubMed ID: 7149908 [TBL] [Abstract][Full Text] [Related]
15. [Suppression of leukocyte migration by autologous and allogeneic tumor extracts in kidney cancer patients]. Novikov DK; Borisenko ID; Shein IA Vopr Onkol; 1978; 24(12):50-5. PubMed ID: 83731 [TBL] [Abstract][Full Text] [Related]
16. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028 [TBL] [Abstract][Full Text] [Related]
17. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814 [TBL] [Abstract][Full Text] [Related]
18. [Cytopherometry in neurologic diseases (author's transl)]. Meyer-Rienecker HJ; Jenssen HL; Köhler H; Werner H Fortschr Neurol Psychiatr Grenzgeb; 1977 Nov; 45(11):615-29. PubMed ID: 336499 [TBL] [Abstract][Full Text] [Related]
19. Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs. Frankenberger B; Pohla H; Noessner E; Willimsky G; Papier B; Pezzutto A; Kopp J; Oberneder R; Blankenstein T; Schendel DJ Clin Cancer Res; 2005 Mar; 11(5):1733-42. PubMed ID: 15755994 [TBL] [Abstract][Full Text] [Related]
20. Circulating cytotoxic anti-RCC antibody responses in renal cell carcinoma patients. Ishibashi M; Matsuda M; Osafune M; Nakano E; Fujioka H; Takaha M; Sonoda T; Kotake T; Watanabe S Hinyokika Kiyo; 1983 Feb; 29(2):121-9. PubMed ID: 6677115 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]